当前位置：首页 > 文献互助 > 互助详情

期刊论文Industrial Pollution of Human Environment复制

用户4I0ROx53Nhq0 1个月前 67 已完结

1. 系统已在2026-02-22 09:10:10对应助文件进行删除

2. 如有需要请重新发布求助信息

注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规

DOI: 10.1001/jama.2023.18382复制

文献链接:复制

其他信息:

上一篇：Wildfires and Human Health

下一篇：Child Asthma Tied to Specific Urban Air Pollutants

互助时间线

2026-02-15 09:10:24 [完结求助]

楼主确认了用户Li619AhX0tl2应助的文件是正确的, 求助状态变成已完结

2026-02-15 09:10:10 [上传文件]

用户Li619AhX0tl2上传了文件(pdf 61.75 KB), 求助状态变成待确认

2026-02-15 09:10:07 [发起求助]

最新发布的求助

Dynamic characterization of circulating tumor DNA in HER2-altered advanced non-small cell lung cancer treated with pyrotinib and apatinib: Exploratory biomarker analysis from PATHER2 study 6分钟前

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial 15分钟前

Trastuzumab Deruxtecan for ERBB2 -Mutant Metastatic Non–Small Cell Lung Cancer With or Without Brain Metastases 37分钟前

Metabolic dysfunction-associated kidney disease: pathogenesis and clinical manifestations 38分钟前

Changes in planned disease management after piflufolastat F¹⁸ PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study. 40分钟前

PSMA-based PET imaging in newly diagnosed, high-risk localized prostate cancer, a National Cancer Institute (NCI) Cancer Moonshot trial. 41分钟前

Regulating Rheumatoid Arthritis From the Perspective of Metabolomics: A Comprehensive Review 1小时前

Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial 1小时前

BPI26-027: Multidisciplinary Practice Patterns in HER2-Mutant NSCLC: Insights to Inform Precision Oncology Education 2小时前

Intralayer bidentate diammoniums for stable two-dimensional perovskites 2小时前

Safety and efficacy of stapokibart, an anti-interleukin-4 receptor α monoclonal antibody, in children aged 6–11 years with moderate-to-severe atopic dermatitis: an open-label single-arm phase Ib/IIa trial 2小时前

Efficacy and safety of stapokibart in adolescents with moderate-to-severe atopic dermatitis: a multicentre randomized double-blind placebo-controlled phase III trial 2小时前